18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma (CA129356-01).
STUDY NOW CLOSED for recruitment
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic
We will investigate the ability of anti-[18F]FACBC PET-CT imaging to detect recurrence of prostate carcinoma in the prostate bed validated by pathologic analysis of prostate bed biopsies and patient follow-up.
At time of scan and pathologic examination and patient follow-up
David M Schuster, MD
United States: Food and Drug Administration
|Emory University Hospital||Atlanta, Georgia 30322|